{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:30:54Z","timestamp":1793493054093,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jdiacomp.2026.109437","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:11:29Z","timestamp":1792167089000},"page":"109437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SGLT2 inhibitors in diabetic biopsy proven MASH patients: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2568-1407","authenticated-orcid":false,"given":"Mona S.","family":"Abdel Monem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie M.","family":"Abbassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmeen A.","family":"Sabry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2026.109437_bb0005","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/hep.32228","article-title":"Global burden of NAFLD and chronic liver disease among adolescents and young adults","volume":"75","author":"Paik","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0010","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0015","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","article-title":"NAFLD as a continuum: from obesity to metabolic syndrome and diabetes","volume":"12","author":"Godoy-Matos","year":"2020","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0025","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.gtc.2016.07.003","article-title":"Nonalcoholic fatty liver disease: pathophysiology and management","volume":"45","author":"Carr","year":"2016","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0030","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1089\/met.2018.0044","article-title":"NASH in nondiabetic endocrine disorders","volume":"16","author":"Wang","year":"2018","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00877","article-title":"NAFLD and diabetes: two sides of the same coin? Rationale for gene-based personalized NAFLD treatment","volume":"10","author":"Xia","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0040","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40273-022-01140-y","article-title":"The economic burden of non-alcoholic steatohepatitis: a systematic review","volume":"40","author":"Witkowski","year":"2022","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0045","doi-asserted-by":"crossref","first-page":"01","DOI":"10.15226\/2374-6890\/3\/1\/00142","article-title":"Recent insights into treatment of non-alcoholic steatohepatitis","volume":"3","author":"Chiappini","year":"2016","journal-title":"J Endocrinol Diabetes"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0050","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/s41598-024-52603-5","article-title":"Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis","volume":"14","author":"Ong Lopez","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0055","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/liv.15209","article-title":"Knowledge of liver fibrosis stage among adults with NAFLD\/NASH improves adherence to lifestyle changes","volume":"42","author":"Carrieri","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/nu14030595","article-title":"Review about psychological barriers to lifestyle modification, changes in diet habits, and health-related quality of life in bariatric endoscopy","volume":"14","author":"Normand","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0065","unstructured":"FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease | FDA n.d. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease (accessed September 1, 2024)."},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0070","unstructured":"FDA Approves Treatment for Serious Liver Disease Known as \u2018MASH\u2019 | FDA n.d. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash (accessed September 5, 2025)."},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0075","series-title":"Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors","author":"Padda","year":"2022"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0080","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41581-024-00836-y","article-title":"Applications of SGLT2 inhibitors beyond glycaemic control","volume":"20","author":"O'Hara","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0085","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/dom.14004","article-title":"Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes","volume":"22","author":"Johansson","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0090","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0095","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2022.101876","article-title":"Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials","volume":"46","author":"Sun","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0105","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/jdi.13237","article-title":"Effects of sodium\u2013glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials","volume":"11","author":"Xing","year":"2020","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0110","doi-asserted-by":"crossref","DOI":"10.1177\/20420188211000243","article-title":"Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data","volume":"12","author":"Arai","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0115","article-title":"Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: a systematic review and meta-analysis","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0120","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0125","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0130","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/hep.31806","article-title":"Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease","volume":"74","author":"Alexopoulos","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.2165","article-title":"The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: a perspective on the pros and cons","volume":"7","author":"Nejadghaderi","year":"2024","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0140","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s40279-023-01927-9","article-title":"The perils of misinterpreting and misusing \u201cpublication bias\u201d in meta-analyses: an education review on funnel plot-based methods","volume":"54","author":"Afonso","year":"2023","journal-title":"Sports Med"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0145","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1002\/sim.10114","article-title":"Standardization and other approaches to meta-analyze differences in means","volume":"43","author":"Hopkins","year":"2024","journal-title":"Stat Med"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0150","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0155","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/jrsm.1429","article-title":"Optimally estimating the sample standard deviation from the five-number summary","volume":"11","author":"Shi","year":"2020","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0160","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0165","unstructured":"Chapter 10: Analysing data and undertaking meta-analyses | Cochrane n.d. https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-10#section-10-10-1 (accessed September 12, 2025)."},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0170","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","article-title":"Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus","volume":"65","author":"Lai","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0175","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2147\/DMSO.S184767","article-title":"Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1\u20133 fibrosis","volume":"11","author":"Seko","year":"2018","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0180","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1515\/med-2018-0059","article-title":"Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease","volume":"13","author":"Miyake","year":"2018","journal-title":"Open Med (Wars)"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0185","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/hepr.13304","article-title":"Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus","volume":"49","author":"Akuta","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0190","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083735","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial","volume":"389","author":"Lin","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2025.102543","article-title":"Efficacy and safety of dapagliflozin compared to pioglitazone in diabetic and non-diabetic patients with non-alcoholic steatohepatitis: a randomized clinical trial","volume":"49","author":"Abdel Monem","year":"2025","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0200","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.curtheres.2017.07.002","article-title":"Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study","volume":"87","author":"Tobita","year":"2017","journal-title":"Curr Ther Res - Clin Exp"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.635556","article-title":"Effect of SGLT2 inhibitors on type 2 diabetes mellitus with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"12","author":"Wei","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107647","article-title":"The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"213","author":"Li","year":"2025","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0215","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.dld.2021.08.017","article-title":"The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: an updated meta-analysis","volume":"54","author":"Mo","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0220","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/jgh3.12473","article-title":"Meta-analysis of the effects of sodium glucose cotransporter 2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes","volume":"5","author":"Sinha","year":"2021","journal-title":"JGH Open"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0225","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.609135","article-title":"Sodium-glucose co-transporter 2 inhibitors for non-alcoholic fatty liver disease in Asian patients with type 2 diabetes: a meta-analysis","volume":"11","author":"Wong","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0230","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0235","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1631\/jzus.B1000105","article-title":"Body mass index, waist circumference, and cardiometabolic risk factors in young and middle-aged Chinese women","volume":"11","author":"Ying","year":"2010","journal-title":"J Zhejiang Univ Sci B"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40256-021-00495-5","article-title":"SGLT2 inhibitors: the dawn of a new era in cardio-metabolic therapeutics","volume":"22","author":"Deedwania","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0245","doi-asserted-by":"crossref","DOI":"10.1186\/s12872-019-1068-5","article-title":"Serum ferritin, an early marker of cardiovascular risk: a study in Chinese men of first-degree relatives with family history of type 2 diabetes","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0250","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1524-6175.2003.01222.x","article-title":"The relationship between systolic blood pressure and cardiovascular risk\u2014results of the Brisighella Heart Study","volume":"5","author":"Borghi","year":"2007","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0255","article-title":"Complications, morbidity and mortality of nonalcoholic fatty liver disease","volume":"111S","author":"Mantovani","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0260","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/hep.30672","article-title":"Defining improvement in nonalcoholic steatohepatitis for treatment trial endpoints: recommendations from the liver forum","volume":"70","author":"Cheung","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0265","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11901-018-0425-7","article-title":"Pathogenesis of NASH: the impact of multiple pathways","volume":"17","author":"Noureddin","year":"2018","journal-title":"Curr Hepatol Rep"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0270","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S1262-3636(14)72689-8","article-title":"Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: a review of the clinical evidence","volume":"40","author":"Scheen","year":"2014","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0275","doi-asserted-by":"crossref","first-page":"122","DOI":"10.36468\/pharmaceutical-sciences.spl.155","article-title":"Dapagliflozin therapy curative effect observation on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus","volume":"82","author":"Liang","year":"2020","journal-title":"Indian J Pharm Sci"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0280","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0285","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2026.109437_bb0290","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S1262-3636(14)72693-X","article-title":"Adverse effects and safety of SGLT-2 inhibitors","volume":"40","author":"Halimi","year":"2014","journal-title":"Diabetes Metab"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872726001820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872726001820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:20:04Z","timestamp":1793492404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872726001820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":58,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1056872726001820"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2026.109437","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 inhibitors in diabetic biopsy proven MASH patients: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2026.109437","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109437"}}